28-day mortality was lower in the tocilizumab group
Usual care: 35%
Rate ratio 0.85 (95% CI, 0.76 to 0.94; p = 0.0028)
Results consistent across all analyses, including those receiving systemic corticosteroids
Patients allocated to tocilizumab were more likely to be discharged from hospital within 28 days
Usual care: 50%
Rate ratio 1.22 (95% CI, 1.12 to 1.33; p < 0.0001)
Not receiving invasive mechanical ventilation at baseline
Patients in tocilizumab group were less likely to reach a composite endpoint of invasive mechanical ventilation or death
Usual care: 42%
Risk ratio 0.84 (95% CI, 0.77 to 0.92; p < 0.0001)
For patients hospitalized with hypoxia and systemic inflammation associated with COVID-19, tocilizumab reduced 28-day mortality, and increased the likelihood of discharge from the hospital by 28-days
Benefit was seen whether the patient was on mechanical ventilation or systemic corticosteroids
The authors state
The RECOVERY trial has shown that for patients hospitalised with severe COVID-19, treatment with tocilizumab reduces mortality, increases the chances of successful hospital discharge, and reduces the chances of requiring invasive mechanical ventilation
These findings require an update to clinical guidelines, which has already begun, and efforts to increase the global availability and affordability of tocilizumab
OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Jointly provided by
NOT ENOUGH CME HOURS
It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan